Switch theme
Sign up to access all valuation multiples
Hofseth BioCare ASA is a Norway based company engaged in the business of development, manufacturing, marketing and sale of marine ingredients such as oil, calcium and protein products. It is also involved in cooperation, participation, and ownership in the businesses engaged in related activities. The group operates in the business segment of producing salmon oil, soluble protein, calcium, and nonwater soluble protein. The brands under the company are OmeGo, PetGo, ProGo, and CalGo. The firm sells products to various segments of the human nutrition market such as sports nutrition, supplements, and health foods, as well as to the market within nutrition to pet and feed industry. It generates the majority of the revenue from the sale of salmon oil.
2009
69
LTM Revenue n/a
LTM EBITDA n/a
$95.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Hofseth BioCare has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Hofseth BioCare achieved revenue of $24.3M and an EBITDA of -$6.4M.
Hofseth BioCare expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Hofseth BioCare valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $18.4M | $24.3M | XXX | XXX | XXX |
| Gross Profit | $2.7M | $4.2M | XXX | XXX | XXX |
| Gross Margin | 15% | 17% | XXX | XXX | XXX |
| EBITDA | -$5.9M | -$6.4M | XXX | XXX | XXX |
| EBITDA Margin | -32% | -26% | XXX | XXX | XXX |
| Net Profit | -$13.0M | -$10.1M | XXX | XXX | XXX |
| Net Margin | -71% | -41% | XXX | XXX | XXX |
| Net Debt | n/a | $14.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Hofseth BioCare's stock price is NOK 2 (or $0).
Hofseth BioCare has current market cap of NOK 863M (or $81.6M), and EV of NOK 1.0B (or $95.3M).
See Hofseth BioCare trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $95.3M | $81.6M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Hofseth BioCare has market cap of $81.6M and EV of $95.3M.
Hofseth BioCare's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Hofseth BioCare's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Hofseth BioCare and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $95.3M | XXX | XXX | XXX |
| EV/Revenue | 3.9x | XXX | XXX | XXX |
| EV/EBITDA | -14.8x | XXX | XXX | XXX |
| P/E | -7.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -72.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpHofseth BioCare's NTM/LTM revenue growth is n/a
Hofseth BioCare's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.3M for the same period.
Over next 12 months, Hofseth BioCare's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Hofseth BioCare's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Hofseth BioCare and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 32% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -26% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 8% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 78% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| SynBiotic | XXX | XXX | XXX | XXX | XXX | XXX |
| Mega Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Procter & Gamble Health | XXX | XXX | XXX | XXX | XXX | XXX |
| Abbott India | XXX | XXX | XXX | XXX | XXX | XXX |
| Sanofi India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Hofseth BioCare acquired XXX companies to date.
Last acquisition by Hofseth BioCare was XXXXXXXX, XXXXX XXXXX XXXXXX . Hofseth BioCare acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Hofseth BioCare founded? | Hofseth BioCare was founded in 2009. |
| Where is Hofseth BioCare headquartered? | Hofseth BioCare is headquartered in Norway. |
| How many employees does Hofseth BioCare have? | As of today, Hofseth BioCare has 69 employees. |
| Who is the CEO of Hofseth BioCare? | Hofseth BioCare's CEO is Mr. Jon Olav Odegard. |
| Is Hofseth BioCare publicy listed? | Yes, Hofseth BioCare is a public company listed on OSL. |
| What is the stock symbol of Hofseth BioCare? | Hofseth BioCare trades under HBC ticker. |
| When did Hofseth BioCare go public? | Hofseth BioCare went public in 2011. |
| Who are competitors of Hofseth BioCare? | Similar companies to Hofseth BioCare include e.g. SynBiotic, Mega Lifesciences, Procter & Gamble Health, Abbott India. |
| What is the current market cap of Hofseth BioCare? | Hofseth BioCare's current market cap is $81.6M |
| What is the current revenue growth of Hofseth BioCare? | Hofseth BioCare revenue growth between 2023 and 2024 was 32%. |
| Is Hofseth BioCare profitable? | Yes, Hofseth BioCare is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
